Novartis sets 2020 target for commercial readiness of cell therapy CMO
Novartis aims to have its Japanese cell therapy CMO commercially ready in the second half of 2020.
Novartis aims to have its Japanese cell therapy CMO commercially ready in the second half of 2020.
CSafe expands its cold chain offering with a series of logistics services suitable for temperature-controlled shipping of biologics.
Sanofi looks to biotech to bolster its pipeline in immuno-oncology indications, with its lead candidate currently in Phase I trials.
Biosana to work collaboratively with the Bioprocessing Technology Institute, aiming to design a highly flexible and cost-effective continuous manufacturing solution.
Securecell introduces Sephara, an in situ filtration membrane with precise pore size for continuous production of antibodies and exosomes.
The abundance of data made available by continuous bioprocessing allows for more control over the process and can thereby improve the quality of the product, says Pall executive.